176 related articles for article (PubMed ID: 32926977)
21. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching.
Lee SW; Ha EK; Yeniova AÖ; Moon SY; Kim SY; Koh HY; Yang JM; Jeong SJ; Moon SJ; Cho JY; Yoo IK; Yon DK
Gut; 2021 Jan; 70(1):76-84. PubMed ID: 32732368
[TBL] [Abstract][Full Text] [Related]
22. Pregnant women with SARS-CoV-2 infection are at higher risk of death and pneumonia: propensity score matched analysis of a nationwide prospective cohort (COV19Mx).
Martinez-Portilla RJ; Sotiriadis A; Chatzakis C; Torres-Torres J; Espino Y Sosa S; Sandoval-Mandujano K; Castro-Bernabe DA; Medina-Jimenez V; Monarrez-Martin JC; Figueras F; Poon LC
Ultrasound Obstet Gynecol; 2021 Feb; 57(2):224-231. PubMed ID: 33320401
[TBL] [Abstract][Full Text] [Related]
23. TNF-α inhibitor-induced psoriasis: A decade of experience at the Cleveland Clinic.
Mazloom SE; Yan D; Hu JZ; Ya J; Husni ME; Warren CB; Fernandez AP
J Am Acad Dermatol; 2020 Dec; 83(6):1590-1598. PubMed ID: 30576759
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort.
Micheroli R; Tellenbach C; Scherer A; Bürki K; Niederman K; Nissen MJ; Zufferey P; Exer P; Möller B; Kyburz D; Ciurea A
Ann Rheum Dis; 2020 Sep; 79(9):1203-1209. PubMed ID: 32581090
[TBL] [Abstract][Full Text] [Related]
25. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM
Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038
[TBL] [Abstract][Full Text] [Related]
26. Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register.
Bechman K; Oke A; Yates M; Norton S; Dennison E; Cope AP; Galloway JB
Rheumatology (Oxford); 2020 Sep; 59(9):2563-2571. PubMed ID: 31998962
[TBL] [Abstract][Full Text] [Related]
27. Successful cessation of tumor necrosis factor inhibitor treatment in rheumatoid arthritis patients and potential predictors for early flare: An observational study in routine clinical care.
Naniwa T; Iwagaitsu S; Kajiura M
Mod Rheumatol; 2020 Nov; 30(6):948-958. PubMed ID: 31814481
[No Abstract] [Full Text] [Related]
28. Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study.
Shin A; Park EH; Dong YH; Ha YJ; Lee YJ; Lee EB; Song YW; Kang EH
Osteoporos Int; 2020 Nov; 31(11):2131-2139. PubMed ID: 32514765
[TBL] [Abstract][Full Text] [Related]
29. The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis.
Lee S; Park YJ; Lee JY
J Korean Med Sci; 2019 Nov; 34(42):e278. PubMed ID: 31674159
[TBL] [Abstract][Full Text] [Related]
30. Immunological alternation in COVID-19 patients with cancer and its implications on mortality.
Cai G; Gao Y; Zeng S; Yu Y; Liu X; Liu D; Wang Y; Yu R; Desai A; Li C; Gao Q
Oncoimmunology; 2021 Jan; 10(1):1854424. PubMed ID: 33489469
[TBL] [Abstract][Full Text] [Related]
31. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.
Wolfe F; Caplan L; Michaud K
Arthritis Rheum; 2006 Feb; 54(2):628-34. PubMed ID: 16447241
[TBL] [Abstract][Full Text] [Related]
32. Infectious risk of add-on leflunomide or tacrolimus versus TNF inhibitors among patients with rheumatoid arthritis receiving background methotrexate: A population-based cohort study.
Shin A; Lee JH; Ha YJ; Lee YJ; Lee EB; Kang EH
Semin Arthritis Rheum; 2022 Aug; 55():152019. PubMed ID: 35567808
[TBL] [Abstract][Full Text] [Related]
33. Association of Sleep-Related Hypoxia With Risk of COVID-19 Hospitalizations and Mortality in a Large Integrated Health System.
Pena Orbea C; Wang L; Shah V; Jehi L; Milinovich A; Foldvary-Schaefer N; Chung MK; Mashaqi S; Aboussouan L; Seidel K; Mehra R
JAMA Netw Open; 2021 Nov; 4(11):e2134241. PubMed ID: 34757409
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of SARS-CoV-2 infection in patients with pulmonary sarcoidosis: A multicenter retrospective research network study.
Hadi YB; Lakhani DA; Naqvi SFZ; Singh S; Kupec JT
Respir Med; 2021 Oct; 187():106538. PubMed ID: 34325226
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity 6 months post COVID-19 mRNA vaccination among adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors.
Dimopoulou D; Tsolia MN; Spyridis N; Maritsi DN
Rheumatology (Oxford); 2023 Feb; 62(SI2):SI205-SI209. PubMed ID: 35788275
[TBL] [Abstract][Full Text] [Related]
36. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
Sormani MP; De Rossi N; Schiavetti I; Carmisciano L; Cordioli C; Moiola L; Radaelli M; Immovilli P; Capobianco M; Trojano M; Zaratin P; Tedeschi G; Comi G; Battaglia MA; Patti F; Salvetti M;
Ann Neurol; 2021 Apr; 89(4):780-789. PubMed ID: 33480077
[TBL] [Abstract][Full Text] [Related]
37. Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis.
Gulácsi L; Zrubka Z; Brodszky V; Rencz F; Alten R; Szekanecz Z; Péntek M
Adv Ther; 2019 Mar; 36(3):721-745. PubMed ID: 30637590
[TBL] [Abstract][Full Text] [Related]
38. Effect of anti-tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in patients with psoriasis-A meta-estimate of pivotal phase 3 trials relevant to decision making during the COVID-19 pandemic.
Syed MN; Shah M; Shin DB; Wan MT; Winthrop KL; Gelfand JM
J Am Acad Dermatol; 2021 Jan; 84(1):161-163. PubMed ID: 32860913
[No Abstract] [Full Text] [Related]
39. Examining the potential direct cardiovascular benefit of tumor-necrosis factor inhibitor in rheumatoid arthritis: Natural and controlled direct effect analyses.
Yoshida K; Harrold LR; Middaugh N; Guan H; Stryker S; Karis E; Solomon DH
Pharmacoepidemiol Drug Saf; 2023 Apr; 32(4):407-415. PubMed ID: 36129396
[TBL] [Abstract][Full Text] [Related]
40. The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry.
Skácelová M; Nekvindová L; Mann H; Závada J; Křístková Z; Vencovský J; Pavelka K; Horák P;
Rheumatol Int; 2022 May; 42(5):803-814. PubMed ID: 35338383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
